Want to see BRNS full AI Analyst Report?
Total Valuation
Barinthus Biotherapeutics has a market cap or net worth of $25.33M. The enterprise value is -$27.65M.
Market Cap$25.33M
Enterprise Value-$27.65M
Share Statistics
Barinthus Biotherapeutics has 40,848,892 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40,848,892
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Barinthus Biotherapeutics’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -58.20%.
Return on Equity (ROE)-0.90
Return on Assets (ROA)-0.68
Return on Invested Capital (ROIC)-58.20%
Return on Capital Employed (ROCE)-0.61
Revenue Per Employee0.00
Profits Per Employee-632.93K
Employee Count105
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Barinthus Biotherapeutics is ―. Barinthus Biotherapeutics’s PEG ratio is -0.07.
PE Ratio―
PS Ratio0.00
PB Ratio0.38
Price to Fair Value0.38
Price to FCF-0.59
Price to Operating Cash Flow-0.70
PEG Ratio-0.07
Income Statement
In the last 12 months, Barinthus Biotherapeutics had revenue of 0.00 and earned -66.58M in profits. Earnings per share was -1.64.
Revenue0.00
Gross Profit-5.86M
Operating Income-54.19M
Pretax Income-68.79M
Net Income-66.58M
EBITDA-62.90M
Earnings Per Share (EPS)-1.64
Cash Flow
In the last 12 months, operating cash flow was -36.44M and capital expenditures -32.00K, giving a free cash flow of -36.48M billion.
Operating Cash Flow-36.44M
Free Cash Flow-36.48M
Free Cash Flow per Share-0.89
Dividends & Yields
Barinthus Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.84
52-Week Price Change-33.12%
50-Day Moving Average0.67
200-Day Moving Average0.79
Relative Strength Index (RSI)41.40
Average Volume (3m)124.73K
Important Dates
Barinthus Biotherapeutics upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateApr 30, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Barinthus Biotherapeutics as a current ratio of 7.77, with Debt / Equity ratio of 16.58%
Current Ratio7.77
Quick Ratio7.77
Debt to Market Cap0.00
Net Debt to EBITDA0.94
Interest Coverage Ratio-1.06K
Taxes
In the past 12 months, Barinthus Biotherapeutics has paid -2.18M in taxes.
Income Tax-2.18M
Effective Tax Rate0.03
Enterprise Valuation
Barinthus Biotherapeutics EV to EBITDA ratio is 0.49, with an EV/FCF ratio of 0.64.
EV to Sales0.00
EV to EBITDA0.49
EV to Free Cash Flow0.64
EV to Operating Cash Flow0.64
Balance Sheet
Barinthus Biotherapeutics has $67.19M in cash and marketable securities with $11.01M in debt, giving a net cash position of $56.18M billion.
Cash & Marketable Securities$67.19M
Total Debt$11.01M
Net Cash$56.18M
Net Cash Per Share$1.38
Tangible Book Value Per Share$1.48
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Barinthus Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast21.30%